-
CBD Helps With This Rare Blistering Skin Disorder, New Study From Avicanna Shows Promising Results In Epidermolysis Bullosa Treatment
Monday, May 13, 2024 - 1:56pm | 402Read More...There is no cure for a rare blistering skin disorder called Epidermolysis Bullosa (EB), but treatments to help alleviate and control the symptoms do exist. The growing body of research suggests cannabinoid-based medicines can ease the pain and severe itching in those with this disorder while also...
-
Krystal Biotech Shares More Than Double During Premarket Monday: What Investors Need To Know
Monday, November 29, 2021 - 9:05am | 308Read More...Krystal Biotech Inc (NASDAQ: KRYS) has announced positive topline results from the GEM-3 Phase 3 trial of investigational beremagene geperpavec (B-VEC, Vyjuvek) for dystrophic Epidermolysis Bullosa (dystrophic EB). DEB is a genetic skin disorder affecting skin and nails that cause...
-
Amryt Pharma's Oleogel-S10 Application Gets FDA Priority Review Tag for Skin Blistering Disorder
Thursday, June 3, 2021 - 8:07am | 320Read More...The FDA has granted priority review status to Amryt Pharma's (NASDAQ: AMYT) marketing application seeking approval for Oleogel-S10 to treat Epidermolysis Bullosa (EB). Oleogel-S10 is a potential treatment for the cutaneous manifestations of Junctional and Dystrophic EB, a...
-
Amicus Therapeutics Building Rare Disease Treatment Strategy; Bank Of America Initiates At Buy
Wednesday, May 18, 2016 - 10:31am | 252Read More...Bank of America's Peter Stapor initiated a Buy rating on Amicus Therapeutics, Inc. (NASDAQ: FOLD) with a price target of $10.00. The leading drug in the company's portfolio is migalastat (Galafold) for a rare disease (Fabry disease), which results in enzyme deficiency and can lead to organ failure...
